Zoledronic acid/ Neridronic acid - USA

PGR decision: May 05, 2020

AIA Review #	Filing Date	Institution Date	Petitioner	Patent	Respondent	Status
PGR2019-00003	10/16/2018	05/07/2019	Grunenthal GmbH	9,867,839	Antecip Bioventures II LLC	Some Challenged Claims Unpatentable

US 9,867,839 (ANTECIP BIOVENTURES II LLC; Exp: Mar. 27, 2035)

1. A method of treating pain associated with a joint comprising: administering neridronic acid in an acid form or a salt form to a patient who has suffered for at least 3 months with 1) pain associated with a joint and 2) a pain intensity of 5 or greater measured using the 0-10 numerical rating scale (NRS) or 5 cm or greater using the 10 cm visual analog scale (VAS).

15. A method of treating pain associated with a joint comprising: orally administering zoledronic acid in an acid form or a salt form to a patient having 1) pain associated with a joint and 2) a pain intensity of 5 or greater measured using the 0-10 NRS or 5 cm or greater using the 10 cm VAS, wherein a total of about 400 mg to about 600 mg of zoledronic acid is administered in 2 or 3 individual doses within a period of about a month.

ORDER:

Claims 1–14 of the ’839 patent are unpatentable; and

Claims 15–30 of the ’839 patent are not shown to be unpatentable.